PeterMarcusRavdinMD
Oncology • San Antonio, TXAssistant Professor, Medicine, University of Texas Medical School, San Antonio
Dr. Ravdin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
7979 Wurzbach Rd
Zeller 4th Floor
San Antonio, TX 78229Phone+1 210-450-3003Fax+1 210-450-1100
Education & Training
University of Wisconsin Hospitals and ClinicsFellowship, Medical Oncology, 1984 - 1987- University of Wisconsin Hospitals and ClinicsResidency, Internal Medicine, 1981 - 1984
University of Miami Leonard M. Miller School of MedicineClass of 1981
Certifications & Licensure
TX State Medical License 1988 - 2026
WI State Medical License 1982 - 1989- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
- Whos Who in Medicine and Healthcare Marquis Whos Who
Clinical Trials
- Paclitaxel or Docetaxel in Treating Women With Advanced Breast Cancer Start of enrollment: 1994 Aug 01
- Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
Publications & Presentations
PubMed
- 160 citations70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by ageMartine Piccart, Laura J. van't Veer, C. Poncet, Josephine M.N. Lopes Cardozo, Suzette Delaloge
The Lancet. Oncology. 2021-04-01 - 39 citationsAssociation Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer.Wendy A. Woodward, William E. Barlow, Reshma Jagsi, Thomas A. Buchholz, Steven Shak
JAMA Oncology. 2020-04-01 - 9 citationsStandard Anthracycline Based Versus Docetaxel-Capecitabine in Early High Clinical and/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III TrialSuzette Delaloge, Martine Piccart, Emiel J. Th. Rutgers, Saskia Litière, Laura J. van't Veer
Journal of Clinical Oncology. 2020-02-21
Journal Articles
- Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast CancerMatthew P Goetz, Thomas J Saphner, Joseph A Sparano, Lynne I Wagner, Peter M Ravdin, Daniel F Hayes, Adam M Brufsky, Della F Makower, Sunil S Badve, Robert J Gray, Wil..., The New England Journal of Medicine
Press Mentions
How the Evolving Link Between Science and Advocacy at SABCS Has Grown Even StrongerFebruary 10th, 2013
Two Drugs Appear to Delay Progression of Breast CancerDecember 7th, 2011- Reversing Trend, Big Drop Is Seen in Breast CancerDecember 15th, 2006
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
